Negative interference by calcium dobesilate in enzymatic assays of free fatty acid

doi:10.3969/j.issn.1673-8640.2016.011.002

Abstract

Abstract:

Objective To investigate the interference of calcium dobesilate in the determination of free fatty acid（FFA） using 6 acetyl-coenzyme A synthetase （ACS）-peroxidase coupled assays and its influence. Methods Calcium dobesilate solution with different concentrations was prepared by pure water,and was added into sera with 2 different FFA concentrations（550 and 1 200 μmol/L）. Serum FFA levels with final concentrations of calcium dobesilate additions（0,2,4,8,16,32 and 64 μg/mL） were determined using 6 ACS enzymatic assays（A,B,C,D,E and F,randomly）. Bias（%） was calculated in serum FFA with final concentration of calcium dobesilate addition（0 μg/mL）. Taking ±5% as an acceptable range of interference,the changes in serum calcium dobesilate levels observed before and after calcium dobesilate administration [baseline,0 h（valley concentration of drug in the stable state）,1 h,2 h,3 h,4 h and 6 h] in 40 participants were monitored by high performance liquid chromatography（HPLC）. Serum calcium dobesilate levels in 40 participants from those taking calcium dobesilate were determined. Results The level of serum calcium dobesilate（0 h） [median（interquartile range）] was 6.64（5.64-7.86）μg/mL. After taking 500 mg,the level of serum calcium dobesilate peaked at 2-3 h. The peak level of serum calcium dobesilate was 15.00（13.63-19.67）μg/mL,and then decreased gradually. The average level in 40 participants was 11.92（5.45-19.22）μg/mL. With the increase of serum calcium dobesilate level,the degree of interference in FFA determination also increased in in vitro experiment. For the low and high concentrations（550 and 1 200 μmol/L） of serum FFA,the biases in 6 ACS enzymatic assays were -0.40% - -65.01% and-0.20% - -52.33% in 8 μg/mL serum calcium dobesilate. The interference degrees of 4 ACS enzymatic assays can be accepted,except B and D. The biases in 6 ACS enzymatic assays were -1.68% - -28.28% and -1.81% - -16.48% in 16 μg/mL serum calcium dobesilate. Except kit A and kit C（high concentration of FFA）,the interference of other kits and kit C（low concentration of FFA） was beyond the acceptable range. The degree of interference was also related with basic serum FFA concentration. Under same calcium dobesilate concentration,the interference with lower concentration of serum FFA was more obvious. Conclusions In ACS enzymatic assays,calcium dobesilate produces a negative interference in the determination of FFA.

Key words: Free fatty acid, Calcium dobesilate, Enzymatic assays, Interference

CLC Number:

R446.1

HOU Li'an, GUO Xiuzhi, QIU Ling, CHENG Xinqi, ZHANG Bo, YU Songlin, FANG Huiling, ZHAO Fang, LIU Qian. Negative interference by calcium dobesilate in enzymatic assays of free fatty acid[J]. Laboratory Medicine, 2016, 31(11): 936-940.

Figures/Tables 3

References 13

1	王昌敏,孟晓辉,宋金萍,等. 两种酶法测定血清游离脂肪酸试剂盒的分析性能比较[J]. 标记免疫分析与临床,2013,20(6) :443-445.
2	陈杰,杨昱,吴阳,等. 血清游离脂肪酸与2型糖尿病患者糖脂代谢相关性的研究[J]. 中国实用医药,2011,6(32):134-135.
3	陆秋涯,迟贞旎,陆怡德. 空腹血清游离脂肪酸与2型糖尿病的关系[J]. 检验医学,2012,27(9):725-727.
4	韩乐,刘晓玲,李荣山,等. 游离脂肪酸对人近曲肾小管上皮细胞HK-2的影响及作用机制[J]. 中国现代医生,2011,49(12):1-3.
5	于佳雪,徐亚伟,肖丹,等. 游离脂肪酸与心血管疾病[J]. 现代生物医学进展,2013,13(10):1979-1982.
6	BENAKIS A,GLASSON B,BOUVIER CA,et al.Metabolism and pharmacokinetics of calcium dobesilate in humans[J]. Therapie,1974,29(2):211-219.
7	GUO X,HOU L,CHENG X,et al.Strong negative interference by calcium dobesilate in sarcosine oxidase assays for serum creatinine involving the trinder reaction[J]. Medicine(Baltimore),2015,94(23):e905.
8	国秀芝,张江涛,侯立安,等. 羟苯磺酸钙对尿酸酶-过氧化物酶偶联法尿酸检测的干扰研究[J]. 中华检验医学杂志,2015,38(9):600-604.
9	Clinical and Laboratory Standards Institute. Interference testing in clinical chemistry[S]. EP7-A2,CLSI,2005.
10	ZHUO HT,BU YS,CAO XM,et al.Relative bioavailability of caecium dobesilate in healthy volunteers[J]. Chin J Clin Pharmacol,2000,16(4):295-297.
11	GUDER WG,HOFFMANN GE,HUBBUCH A,et al.Multicentre evaluation of enzymatic method for creatinine determination using a sensitive colour reagent[J]. J Clin Chem Clin Biochem,1986,24(11):889-902.
12	JAVADZADEH A,GHORBANIHAGHJO A,ADL FH,et al.Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy[J]. Mol Vis,2013,19:62-68.
13	李新征,陈宝炳,康云平. 非酒精性脂肪肝患者血清游离脂肪酸与胰岛素抵抗的关系[J]. 检验医学,2012,27(1):48-49.

FFA （μmol/L）	试剂盒
FFA （μmol/L）	试剂盒	2	4	8	16	32	64
550	A	-0.40	-0.58	-0.98	-1.68	-3.53	-6.53
	B	-2.23	-4.47	-9.50	-16.76	-30.73	-54.19
	C	-0.60	-1.57	-2.72	-5.63	-11.25	-20.15
	D	-5.18	-8.11	-15.44	-28.28	-46.14	-65.11
	E	-0.60	-2.06	-3.85	-7.16	-13.61	-24.35
	F	-0.85	-0.44	-3.54	-6.36	-12.54	-21.44
1 200	A	-0.16	-0.90	-0.66	-1.81	-3.29	-5.12
	B	-1.53	-3.06	-5.87	-10.71	-19.90	-37.76
	C	-0.20	-0.45	-1.35	-4.40	-8.93	-17.28
	D	-2.35	-4.60	-7.74	-16.48	-30.09	-52.33
	E	-0.47	-1.43	-2.42	-5.07	-10.04	-18.19
	F	-1.07	-1.62	-3.02	-6.16	-10.03	-19.28

FFA （μmol/L）	试剂盒
FFA （μmol/L）	试剂盒	2	4	8	16	32	64
550	A	-0.40	-0.58	-0.98	-1.68	-3.53	-6.53
	B	-2.23	-4.47	-9.50	-16.76	-30.73	-54.19
	C	-0.60	-1.57	-2.72	-5.63	-11.25	-20.15
	D	-5.18	-8.11	-15.44	-28.28	-46.14	-65.11
	E	-0.60	-2.06	-3.85	-7.16	-13.61	-24.35
	F	-0.85	-0.44	-3.54	-6.36	-12.54	-21.44
1 200	A	-0.16	-0.90	-0.66	-1.81	-3.29	-5.12
	B	-1.53	-3.06	-5.87	-10.71	-19.90	-37.76
	C	-0.20	-0.45	-1.35	-4.40	-8.93	-17.28
	D	-2.35	-4.60	-7.74	-16.48	-30.09	-52.33
	E	-0.47	-1.43	-2.42	-5.07	-10.04	-18.19
	F	-1.07	-1.62	-3.02	-6.16	-10.03	-19.28

[1]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[2]	HAN Guang, XU Qiongfeng, DUAN Shumin, LUO Jiahuan, WANG Yunxiu, ZHANG Xiujuan, WAN Zemin, KE Peifeng, HUANG Xianzhang. Evaluation of the interference of serum index in the determination of prealbumin by immunoscattering turbidimetry according to CLSI EP07-A3 document [J]. Laboratory Medicine, 2022, 37(2): 108-111.
[3]	XUE Yan, XU Li, DANG Liheng, WANG Chao, CUI Yaqiong, WANG Ping, WANG Ning, ZHANG Xinjie, LIU Yang. Interference of high levels of bilirubin on lymphocyte subset determination in peripheral blood by flow cytometry and its elimination methods [J]. Laboratory Medicine, 2022, 37(12): 1169-1173.
[4]	WANG Wei, WANG Lei. Influence of pre-analysis factors on clinical biochemical test results [J]. Laboratory Medicine, 2021, 36(4): 357-361.
[5]	JIA Keke, SUN Wenyuan, NIE Rui, CUI Liyan. Detection and prevention of common interference in turbidimetric immunoassay [J]. Laboratory Medicine, 2021, 36(4): 362-368.
[6]	OU Yuanzhu, GONG Jingkai, LIN Feiran, TANG Liping, ZHU Yuqing, LIU Jia, WANG Hualiang. Interference effects of hemoglobin,bilirubin and chyle on the measurement of plasma ammonia by dry chemistry method and enzymatic assay method [J]. Laboratory Medicine, 2021, 36(11): 1146-1150.
[7]	JIANG Wenrong, MIAO Yingxin, WANG Su, WANG Shiwen, ZHAO Hu, ZHANG Yanmei. Influence of common clinical interference factors on the detection of ctDNA EGFR T790M mutation [J]. Laboratory Medicine, 2020, 35(5): 399-404.
[8]	ZHU Wenkui, XU Qi, CHEN Jin. Correlations of serum calcium and free fatty acid with metabolic syndrome among elders in community [J]. Laboratory Medicine, 2018, 33(5): 407-410.
[9]	JIANG Haoqin, GU Jianfei, CHEN Jian, WANG Ji, WANG Kaijun, LÜ Yuan. Performance verification and interference factors of SYSMEX XN-9000 hematology analyzer for the determinations of reticulocyte count and parameters according to CAP accreditation requirements [J]. Laboratory Medicine, 2018, 33(5): 431-436.
[10]	WANG Zhengyin, YIN Yuan, WANG Weiling. Research progress in the methods for creatinine determination and the interference of common drugs on creatinine determination [J]. Laboratory Medicine, 2018, 33(4): 370-373.
[11]	XIE Liangcai, FAN Wen, XU Lei, XU Rong, LIU Tianchun. False negative interference of RF on serum HBeAg by ELISA [J]. Laboratory Medicine, 2017, 32(9): 765-768.
[12]	TANG Jibin, GUAN Jingyi, ZHANG Sheng, LI Xuguang, ZHANG Wen, ZHOU Jiali. Relationship between serum free fatty acid and non-insulin-dependent diabetes mellitus metabolic disorder [J]. Laboratory Medicine, 2017, 32(6): 500-503.
[13]	GU Keping, WANG Yaping, YU Wei, ZHANG Min, GONG Mengjiao, JIANG Yuhai. Receiver operating characteristic curve for free fatty acid determination in patients with coronary heart disease [J]. Laboratory Medicine, 2017, 32(5): 367-369.
[14]	LIU Juanjuan, XUE Zhixin, WANG Baoxue, LI Yanan, SU Yan, ZHOU Zeqi. Minimizing interference in the detection of lipopolysaccharide in serum [J]. Laboratory Medicine, 2017, 32(2): 131-134.
[15]	NI Chong, YIN Yuan, WANG Weiling. Interference of Chinese patent medicine on determination results and its strategy [J]. Laboratory Medicine, 2017, 32(2): 149-152.